Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again

Mar 18 2017

• By Bridget Silverman

Related Content

Buying ZS Pharma Could Give AstraZeneca Best-In-Class Blockbuster

Nov 06 2015

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

Dec 04 2016

AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter

May 27 2016

Opana ER Looking At REMS – Or Worse – After US FDA Panel Weighs Intravenous Abuse Risk

Mar 14 2017

US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say

Mar 15 2017

Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance

Mar 14 2017

Blood Cancer Sector More Competitive After Keytruda Approval

Mar 15 2017

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

Nov 04 2016

Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity

Feb 27 2017

Related Companies

Novartis AG

Merck & Co., Inc.

AstraZeneca PLC

Pfizer Inc.

Bristol Myers Squibb Company

GSK plc

Sumitomo Pharma Co., Ltd.

Inspirion Delivery Technologies LLC

Seagen Inc.

Daiichi Sankyo Co., Ltd.

Endo, Inc.

Additional Topics

United States Approvals Complete Response Letters Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window